SecBot SecBot
424B5 ·Filed May 14, 2026

GILD

GILEAD SCIENCES, INC.
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago SEC0001104659-26-060745
Notable filing: 424B5
Actionable Insight • Neutral

This is a routine investment-grade debt capital markets transaction by a cash-rich, growing biopharma. The offering size and pricing will determine the exact impact on leverage ratios. Monitor pricing for spread relative to existing GILD curve, a tight spread signals strong credit confidence. The raised guidance and strong Q1 support the credit profile. No material equity dilution or common stock read-through.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$132.06
T+0 close · May 14, 2026 · via day close
Latest settled
+0.73%
T+60 · $133.02
Vs SPY
−2.60%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 14 $132.06entry
  2. T+1 · 6mo ago −1.89%α −0.66% · $129.57
  3. T+5 · 6mo ago −1.25%α −0.53% · $130.41
  4. T+20 · 5mo ago −4.90%α −4.04% · $125.59
  5. T+60 · 3mo ago +0.73%α −2.60% · $133.02

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Gilead Sciences filed a preliminary 424B5 prospectus supplement for a multi-tranche senior unsecured note offering with undisclosed aggregate principal amount and interest rates. The filing follows strong Q1 2026 results (total revenue +4% YoY to $7.0B, product sales ex-Veklury +8% to $6.8B, raised full-year guidance) and a $4.7B term loan facility entered in April 2026. Proceeds are earmarked for general corporate purposes including potential M&A. The debt raise is a routine refinancing/capital structure move for an investment-grade issuer, not a distress signal.

Key Facts

  • Offering of four series of senior unsecured notes with undisclosed aggregate principal amount, interest rates, and maturities
  • Net proceeds to be used for general corporate purposes including acquisitions, investments, or strategic transactions
  • Filed 7 days after Q1 2026 earnings: total revenue $7.0B (+4% YoY), product sales ex-Veklury $6.8B (+8% YoY), non-GAAP diluted EPS $2.03 vs $1.81 YoY
  • Full-year 2026 product sales guidance raised to $30.0B-$30.4B from prior $29.6B-$30.0B
  • As of March 31, 2026: $8.6B cash/marketable securities, $22.2B total debt, $23.4B stockholders' equity
  • Notes are senior unsecured obligations ranking equally with $21.1B of existing unsecured debt
  • Joint book-running managers: Barclays, BofA Securities, Citigroup
  • Notes not listed on any exchange; no public markets currently exist

Financial Impact

Undisclosed offering size, net proceeds will increase total debt from $22.2B (pro forma for $1.1B drawn on $4.7B term loan facility). Q1 2026 operating cash flow was $2.5B.

debtinterest expensecash

Risk Factors

  • Undisclosed offering size could meaningfully increase leverage if large relative to existing $22.2B debt
  • Proceeds used for M&A could introduce integration risk or change credit profile
  • Notes structurally subordinated to $3.7B of subsidiary obligations
  • No established secondary market for the notes, liquidity risk for bondholders

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
79% bullish (39 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001104659-26-060745
Document: 0001104659-26-060745-index-headers.html0001104659-26-060745
Document: 0001104659-26-060745-index.html0001104659-26-060745
Document: 0001104659-26-060745.txt0001104659-26-060745

Track record

30 reports on GILD

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +22.38% at T+60 after the Aug 13, 2026 report. 5 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $167.58 Now $167.58 +0.00% settles Feb 16
  2. Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $167.71 Now $167.58 −0.08% settles Feb 12
  3. Nov 13, 20264d ago Court Ruling Bullish 4/10 Entry $170.99 Now $167.58 −1.99% settles Feb 12
  4. Nov 12, 20264d ago 144 Neutral 2/10 Entry $168.08 Now $167.58 −0.30% settles Feb 11
  5. Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $170.87 Now $167.58 −1.93% settles Feb 8
  6. Nov 6, 202610d ago 144 Neutral 2/10 Entry $169.32 Now $167.58 −1.03% settles Feb 5
  7. Nov 4, 202612d ago 144 Neutral 3/10 Entry $167.57 Now $167.58 +0.01% settles Feb 3
  8. Oct 30, 202617d ago 144 Neutral 3/10 Entry $170.33 Now $167.58 −1.61% settles Jan 29
  9. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $170.68 Now $167.58 −1.82% settles Jan 28
  10. Oct 22, 202625d ago Institutional Cluster Bearish 4/10 Entry $156.04 Now $167.58 −7.40% settles Jan 21
Showing 10 of 30

US Market Status

Market Closed · Opens Wed (11h 49m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 14, 2026